Hepatitis D

Infectious Diseases
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

PharmaEssentia
PharmaEssentiaMA - Burlington
1 program
1
Ursodeoxycholic acidPhase 21 trial
Active Trials
NCT05467553UnknownEst. Aug 2025
GS
Gilead SciencesFOSTER CITY, CA
2 programs
HDV-AbN/A1 trial
HDV-AbN/A
Active Trials
NCT05394623Unknown5,000Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
PharmaEssentiaUrsodeoxycholic acid
Gilead SciencesHDV-Ab

Clinical Trials (2)

Total enrollment: 5,000 patients across 2 trials

NCT05467553PharmaEssentiaUrsodeoxycholic acid

A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

Start: Feb 2023Est. completion: Aug 2025
Phase 2Unknown

Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)

Start: Nov 2022Est. completion: Jul 20235,000 patients
N/AUnknown

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space